A novel B-ring modified homocamptothecin, 12-cl-hcpt, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38

Anti-Cancer Drug Design

Volumn 16, Issue 1, 2001, Pages 27-36

  Bailly, C ^a   Laine, W ^a   Baldeyrou, B ^a   Demarquay, D ^a   Huchet, M ^a   Coulomb, H ^a   Lanco, C ^a   Lavergne, O ^a   Bigg, D C H ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Antitumour drug; Cytotoxicity; DNA cleavage; Homocamptothecin; Topoisomerase I

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; DNA; DNA TOPOISOMERASE INHIBITOR; GLYCOPROTEIN P; HOMOCAMPTOTHECIN; IRINOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DNA CLEAVAGE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL DIVISION; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DNA, SUPERHELICAL; DOXORUBICIN; ENZYME INHIBITORS; HT29 CELLS; HUMANS; PLASMIDS;

EID: 0035204463     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Topoisomerase I poisons and suppressors as anticancer drugs
2. Homocamptothecin, an E-ring modified camptothecin analog, generates new topoisomerase I-mediated DNA breaks
3. CPT-11 in gastrointestinal cancer
4. Reactions with indole derivatives. XVII. The biogenetically oriented total synthesis of DL-campothecin and 7-chlorocamptothecin
5. Chemistry of the camptothecins in the bloodstream. Drug stabilization and optimization of activity
6. A randomized phase II trial comparing irinotecan + 5FU/folinic acid to the same schedule of 5FU/FA in patients with metastatic colorectal cancer as front line chemotherapy
7. Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin
8. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin
9. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II
10. Unusual potency of BN80915, a novel E-ring modified camptothecin, towards human colon adenocarcinoma cells
11. BN80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities
12. Homocamptothecins: Synthesis and antitumor activity of novel E-ring-modified camptothecin analogues
13. Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins
14. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties
15. Digital morphonuclear analyses of sensitive versus resistant neoplastic cells to vinca-alkaloid, alkylating, and intercalating drugs
16. Base sequence selectivity of topoisomerase inhibitors suggests a common model for drug action
17. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
18. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I
19. Flow cytometric monitoring of anthracycline accumulation after anti-neoplastic ether phospholipid treatment
20. Anti-tumour profile of BN80915, a novel E-ring modified topoisomerase I inhibitor
21. Weekly irinotecan, leucovorin, and fluorouracil is superior to daily x5 LV/FU in patients with previously untreated metastatic colorectal cancer
22. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: A-ring modified and 7,10-disubstituted camptothecins
23. Ring closure and rearrangement reactions of 4-azido-2-oxoquinoline-3-carboxylates and 4-azidocoumarin-3-carboxylates
24. Clinical applications of the camptothecins
25. Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin
26. Camptothecin and taxol: Discovery to clinic-Thirteenth Bruce F. Cain memorial award lecture
27. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata